Sign In
Buy CRL
$185.79
+5.92 (+3.29%)
At Close: Jun 04, 2026
Charles River Laboratories International, Inc. (NYSE:CRL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants James Foster - Chairman, Presiden
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
08:00am, Monday, 08'th Sep 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Baird and Morgan Stanley Conferences.
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
09:51am, Thursday, 04'th Sep 2025
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
Charles River Stock May Benefit From Joining EASYGEN Consortium
11:26am, Monday, 01'st Sep 2025
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing
08:00am, Tuesday, 26'th Aug 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .
Interpreting Charles River (CRL) International Revenue Trends
10:15am, Monday, 11'th Aug 2025
Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript
01:30pm, Wednesday, 06'th Aug 2025
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing
12:50pm, Wednesday, 06'th Aug 2025
Charles River Laboratories International Inc. CRL stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.
Charles River: Margin Fears Outweigh Solid Q2
12:47pm, Wednesday, 06'th Aug 2025
Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:30am, Wednesday, 06'th Aug 2025
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Str
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
10:26am, Wednesday, 06'th Aug 2025
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
09:15am, Wednesday, 06'th Aug 2025
Charles River Laboratories (CRL) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.5 per share. This compares to earnings of $2.8 per share a year ago.
Charles River raises profit forecast on growing demand for drug development services
07:55am, Wednesday, 06'th Aug 2025
Charles River Laboratories on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4%
Charles River Laboratories Announces Second-Quarter 2025 Results
07:00am, Wednesday, 06'th Aug 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2025 Results.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
11:08am, Wednesday, 30'th Jul 2025
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
